Saturday 17 October 2026 Export BHVN’s income statement to Excel — free account

Biohaven Ltd.

In the quarter to June 2026, EPS grew 53.1%, free cash flow grew 49.1% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

10.78 0.65 −5.69%

Follow BHVN

Alert me

Market cap: $1.7B
P/E: 0.0×
Fwd P/E: −49.0×
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 33.14

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	4	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 14.66%

Capital & Financial Ratios $m

Market Cap 1,730.00

Revenue 995.42

Net Income (586.84)

Free Cash Flow (512.10)

Net Debt (8.39)

Current Ratio 4.73

Debt/Equity 21.23

P/E ratio 0.00

Fwd P/E (49.00)

P/S ratio 1.63

P/B ratio 132.86

Past 5Y EPS Growth —

This Y EPS Growth 62.91%

Next Y EPS Growth 2.45%

Next Y revenue growth (100.00%)

Next 5Y EPS Growth 32.13%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 32.10%

10-year low 10-year high

P/B against its own 10 years 92.61%

10-year low 10-year high

EV/Sales against its own 10 years 36.08%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	382	486	319	268
Receivables	13	3	—	—
Inventory	—	—	—	—
Other	12	3	2	2
	442	538	368	297

	2023	2024	2025	Q'26
Payables	16	18	12	12
ST’ Debt	—	—	—	—
Other	—	85	—	—
	55	154	116	63

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	47.24%	0.00%	(54.11%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(150)	(85)	—	—	—
’25	(165)	(168)	(146)	(131)	(609)
’24	(103)	(168)	(141)	(171)	(582)
’23	(78)	(44)	(95)	(115)	(332)
’22	(59)	(68)	(96)	(75)	(298)
’21	(206)	(227)	320	(33)	(146)
’20	(151)	(176)	(164)	415	(76)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(150)	(86)	—	—	—
’25	(166)	(168)	(146)	(131)	(610)
’24	(103)	(171)	(142)	(170)	(586)
’23	(78)	(45)	(96)	(115)	(335)
’22	(59)	(89)	(100)	(76)	(304)
’21	(207)	(228)	321	(33)	(147)
’20	(174)	(177)	(184)	415	(120)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.88)	(0.91)	—	—	—
’25	(2.17)	(1.94)	(1.64)	(1.21)	(6.86)
’24	(2.20)	(3.64)	(1.70)	(1.85)	(9.28)
’23	(1.03)	(1.32)	(1.50)	(1.81)	(5.73)
’22	(2.97)	(6.21)	(1.75)	(3.32)	(12.75)
’21	(4.21)	(3.23)	(1.38)	(3.01)	(5.43)
’20	(3.07)	(3.08)	(3.27)	(3.62)	(3.01)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	5.42	12.35	26.80	7.48	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	17.86	44.29	62.21	44.28
People
People	Employees	12	42	63	647	825	928	202	239	256	274
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	(0.11)	(0.30)	0.00	—	—	—
	EBT	(63)	(126)	(240)	(528)	(119)	(212)	(570)	(410)	(846)	(737)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(64)	(127)	(241)	(529)	(119)	(214)	(570)	(408)	(846)	(739)
	Depreciation	0	—	4	1	0	1	1	7	8	10
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(5.04)	(5.00)	(6.15)	(10.91)	(3.01)	(5.43)	(12.75)	(5.73)	(9.28)	(6.86)
	Cash flow	(2.34)	(3.40)	(5.03)	(7.78)	(1.93)	(3.70)	(6.65)	(4.66)	(6.38)	(5.66)
	Capex	0.00	(0.02)	(0.11)	(0.08)	(1.12)	(0.02)	(0.14)	(0.04)	(0.04)	(0.01)
	Free cash flow	(2.34)	(3.42)	(5.14)	(7.86)	(3.05)	(3.73)	(6.79)	(4.70)	(6.42)	(5.67)
	Book value	(0.14)	4.74	3.85	(0.15)	(9.96)	0.88	12.04	6.01	4.64	0.48
	Shares, m	13	28	39	48	39	39	45	71	91	108
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	0.00	—	—	—	—
	P/S	—	—	—	—	53.04	9.07	—	—	—	—
	P/B	—	—	—	—	0.00	156.42	—	—	—	—
	EV/Sales	—	—	—	—	52.75	10.14	—	—	—	—
	EV/FCF	—	—	—	—	(27.93)	(36.22)	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(30)	(95)	(197)	(377)	(76)	(146)	(298)	(332)	(582)	(609)
	Capex	0	(1)	(4)	(4)	(44)	(1)	(6)	(3)	(4)	(1)
	Free cash flow	(30)	(95)	(201)	(381)	(120)	(147)	(304)	(335)	(586)	(610)
Balance, $m
Balance, $m	Working capital	16	127	253	262	326	53	497	387	384	252
	Total debt	1	—	118	248	267	3	31	—	—	239
	Net debt	(23)	(131)	(146)	(69)	(88)	(73)	(470)	(382)	(486)	(80)
	Shareholders’ equity	(2)	132	151	(7)	(392)	35	539	428	423	52
Returns, %
Returns, %	ROA	(440.53)	(160.08)	(110.29)	(166.74)	(23.01)	(51.58)	(141.89)	(69.48)	(150.03)	(138.54)
	ROIC	0.00	(13,367.54)	(3,004.63)	0.00	0.00	0.00	(515.93)	(590.46)	0.00	0.00
	ROE	289.80	(320.22)	(170.33)	(737.03)	59.39	119.61	(198.89)	(84.44)	(198.83)	(310.75)

Negative figures in brackets.

All 10 years →

Latest quarter Jun 2021

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MESO Mesoblast Limited	$1.8B	— (loss-making)	—	−13.41% (below 0%: shrinking)	n/m	−89.23% (below 0%: shrinking)	(353.35%)	(909.40%)	Compare
URGN Urogen Pharma	$1.8B	— (loss-making)	— (loss-making)	+199.22% (above 0%: growing)	n/m	+17.26% (above 0%: growing)	90.93%	0.15%	Compare
XNCR Xencor, Inc.	$1.8B	— (loss-making)	— (loss-making)	+17.46% (above 0%: growing)	n/m	−52.91% (below 0%: shrinking)	100.00%	(72.37%)	Compare
VIR Vir Biotechnology, Inc.	$1.8B	— (loss-making)	— (loss-making)	+19,582.54% (above 0%: growing)	n/m	+200.47% (above 0%: growing)	100.00%	30.75%	Compare
SEPN Septerna, Inc.	$1.8B	— (loss-making)	— (loss-making)	+22,375.63% (above 0%: growing)	n/m	−9.01% (below 0%: shrinking)	100.00%	(62.95%)	Compare
BHVN Biohaven Ltd.	$1.7B	— (loss-making)	— (loss-making)	+131.43% (above 0%: growing)	n/m	+49.13% (above 0%: growing)	0.00%	0.00%
TRVI Trevi Therapeutics, Inc.	$1.7B	— (loss-making)	—	—	n/m	−73.77% (below 0%: shrinking)	0.00%	0.00%	Compare
NUVB Nuvation Bio Inc.	$1.7B	— (loss-making)	— (loss-making)	+555.64% (above 0%: growing)	n/m	+10.62% (above 0%: growing)	70.11%	(161.06%)	Compare
ZBIO Zenas BioPharma, Inc.	$1.7B	— (loss-making)	— (loss-making)	—	n/m	−37.12% (below 0%: shrinking)	100.00%	(10,765.90%)	Compare
Median of peers	$1.8B	—	—	+377.43%	—	−23.06%	95.47%	(67.66%)

All 614 Biotechnology stocks →

Biohaven Ltd. (BHVN) key facts

Biohaven Ltd. (BHVN) is a Biotechnology company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, BHVN traded at $10.78, a market capitalization of $1.7 billion.
Return on equity was −310.8% and debt-to-equity 21.23.

Source: company filings (standardised) and stockrow calculations.